The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1433894
This article is part of the Research Topic Drug Discovery in Cancer Research: Success Stories and Open Challenges View all 20 articles
Treatment with ensartinib shows good response to SQSTM1-ALK fusion in lung adenocarcinoma
Provisionally accepted- 1 First Affiliated Hospital, Guangxi Medical University, Nanning, China
- 2 Other, Shanghai, China
Lung cancer is a prevalent malignancy, with the rearrangement of the anaplastic lymphoma kinase (ALK) gene being responsible for a minority of cases of non-small cell lung cancer (NSCLC).NSCLC patients harboring ALK fusion proteins demonstrate sensitivity to ALK tyrosine kinase inhibitors (TKIs).In this report, we describe the case of a female patient with metastatic lung adenocarcinoma, identified through NGS to carry a rare inverted SQSTM1-ALK (S5, A20) fusion.The patient received ensartinib as first-line therapy, resulting in a partial response (PR).At the time of publication, the patient's condition remained favorable.We have, for the first time, identified the presence of SQSTM1-ALK fusion in pericardial effusion, with the favorable response to ensartinib validating the oncogenic potential of SQSTM1-ALK fusion.The substantial advancements and extensive utilization of NGS have facilitated the identification of rare fusion variants.
Keywords: SQSTM1-ALK, rearrangement, lung cancer, targeted therapy, ensartinib
Received: 16 May 2024; Accepted: 14 Oct 2024.
Copyright: © 2024 WANG, JIANG, Guo, Liu, Liu, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jianji Guo, First Affiliated Hospital, Guangxi Medical University, Nanning, China
Tao Liu, First Affiliated Hospital, Guangxi Medical University, Nanning, China
Zhen Liu, Other, Shanghai, China
Dongdong Wang, Other, Shanghai, China
Honglin Li, Other, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.